Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682796 · ClinicalTrials.gov registry record · Phase 1
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
A Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Triphase Research and Development III.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 7
- Study locations
NCT03682796: Completed Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Triphase Research and Development III.
NCT03682796 is a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin that has completed, run by Triphase Research and Development III. The registered enrollment target is 32 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03682796, a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, has completed, sponsored by Triphase Research and Development III.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.
Primary Outcome
To determine the MTD of TRPH-222
Conditions Studied
Interventions
- DRUG TRPH-222
Study Locations (7)
Arizona
- Banner MD Anderson - Gilbert
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Tennessee
- Sarah Cannon Research Institute at Tennessee Oncology - Nashville
Ontario
- Princess Margaret Cancer Centre - Toronto
Quebec
- Jewish General Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2021-11-17 |
| Phase | Phase 1 |
What the finished NCT03682796 record still lists
NCT03682796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower).
The record links to 7 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which TRPH-222 is the first listed.
NCT03682796 lists 7 locations in 7 states (Arizona, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT03682796 about?
NCT03682796 is a clinical study titled "Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma". This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.
What is the current status of trial NCT03682796?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-10-15. Estimated completion is 2021-11-17.
What conditions does trial NCT03682796 study?
This clinical trial studies the following conditions: Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular.
What interventions are being tested in trial NCT03682796?
The interventions under investigation include: TRPH-222 (DRUG).
Who is sponsoring clinical trial NCT03682796?
This trial is sponsored by Triphase Research and Development III, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03682796 being conducted?
This trial has 7 study locations across Arizona, New York, Ohio, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03682796's enrollment target sits among peer trials
32 209th of 299 higher than 88 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI